WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015157409) MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/157409    International Application No.:    PCT/US2015/024909
Publication Date: 15.10.2015 International Filing Date: 08.04.2015
IPC:
A61K 31/282 (2006.01)
Applicants: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center Athens, Georgia 30602-7411 (US)
Inventors: DHAR, Shanta; (US).
PATHAK, Rakesh; (US).
MARRACHE, Sean; (US)
Agent: CAMPBELL, Keith; (US)
Priority Data:
61/976,559 08.04.2014 US
PCT/US2015/018720 04.03.2015 US
PCT/US2014/069997 12.12.2014 US
Title (EN) MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG
(FR) PROMÉDICAMENT À BASE DE PLATINE (IV) CIBLANT LES MITOCHONDRIES
Abstract: front page image
(EN)Pt(IV) compounds include a mitochondria targeting moiety. One example of a Pt(IV) compound having a mitochondria targeting moiety is a Pt(IV) cisplatin-based compound. Upon reduction, the mitochondrial targeting moieties are released resulting in a Pt(II) therapeutic agent. Pt(IV) compounds including a mitochondria targeting moiety can be included in nanoparticles. The compounds or nanoparticles can be used to treat, for example, cancer.
(FR)Les composés à base de Pt(IV) comprennent une fraction de ciblage des mitochondries. Un exemple d'un composé à base de Pt(IV) ayant une fraction de ciblage des mitochondries est un composé à base de Pt(IV) cisplatine. Lors de la réduction, les fractions de ciblage des mitochondries sont libérées, résultant en un agent thérapeutique Pt(II). Les composés à base de Pt(IV) comprenant une fraction de ciblage des mitochondries peuvent être inclus dans des nanoparticules. Les composés ou nanoparticules peuvent être utilisés pour traiter, par exemple, le cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)